IMTX

Immatics NV

Add to Watchlist

Advanced Chart

6.180

-0.14(-2.215%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

6.470

Open

6.360

VWAP

6.29

Vol

189.90K

Mkt Cap

751.18M

Low

6.170

Amount

1.19M

EV/EBITDA(TTM)

Total Shares

103.05M

199.90M

EV/OCF(TTM)

P/S(TTM)

4.56

Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

13.05M

-78.49%

-0.410

-190.51%

13.05M

-75.53%

-0.385

+355.57%

13.05M

-36.37%

-0.359

+93.39%

Estimates Revision

The market is revising Downward the revenue expectations for Immatics N.V. (IMTX) for FY2025, with the revenue forecasts being adjusted by -15.56% over the past three months. During the same period, the stock price has changed by 45.75%.

Revenue Estimates for FY2025

Revise Downward

-15.56%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-11.34%

In Past 3 Month

Stock Price

Go Up

+45.75%

In Past 3 Month

4 Analyst Rating

86.08% Upside

Wall Street analysts forecast IMTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMTX is 11.50 USD with a low forecast of 10.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

86.08% Upside

Current: 6.180

Low

10.00

Averages

11.50

High

13.00

86.08% Upside

Current: 6.180

Low

10.00

Averages

11.50

High

13.00

Deutsche Bank

Buy

initiated

$10

2025-05-28

Reason

Deutsche Bank

Price Target

$10

2025-05-28

initiated

Buy

Reason

Deutsche Bank initiated coverage of Immatics with a Buy rating and $10 price target. The firm likes the company's setup to tackle cutaneous melanoma. Immatics' TCR-based therapies have produced "mixed" clinical results in early- and mid-stage trials to date, which has the shares are trading at around cash levels, the analyst tells investors in a research note. However, Deutsche believes IMA203 may have a place in serving the unmet second-line cutaneous melanoma population, particularly if it can generate a 75% one-year overall survival rate from the pivotal Phase 3 SUPRAME trial data expected late 2026.

Cantor Fitzgerald

Eric Schmidt

Buy

Reiterates

n/a

2025-04-01

Reason

Cantor Fitzgerald

Eric Schmidt

Price Target

n/a

2025-04-01

Reiterates

Buy

Reason

B of A Securities

Alex Stranahan

Strong Buy

Maintains

$16 → $15

2024-11-19

Reason

B of A Securities

Alex Stranahan

Price Target

$16 → $15

2024-11-19

Maintains

Strong Buy

Reason

BofA lowered the firm's price target on Immatics to $15 from $16 and keeps a Buy rating on the shares following Q3 earnings, which included first clinical data for IMA402, the company's TCR bispecific targeting PRAME, and updated timelines across the company's therapies. The early data for '402, in addition to recent progress for IMA203, bolsters confidence in Immatics' TCR approach ahead of additional updates next year, the analyst tells investors.

Piper Sandler

Joseph Catanzaro

Buy

Initiates

$19

2024-10-07

Reason

Piper Sandler

Joseph Catanzaro

Price Target

$19

2024-10-07

Initiates

Buy

Reason

Piper Sandler initiated coverage of Immatics with an Overweight rating and $19 price target. The company's platforms, specifically its PRAME-targeting portfolio, has broad utility across solid tumors, the analyst tells investors in a research note. The firm thinks IMA203 is positioned as a best-in-indication cell therapy offering within post-PD-1 melanoma. It also sees significant opportunity outside of melanoma, particularly with IMA203CD8.

Cantor Fitzgerald

Eric Schmidt

Buy

Reiterates

n/a

2024-09-09

Reason

Cantor Fitzgerald

Eric Schmidt

Price Target

n/a

2024-09-09

Reiterates

Buy

Reason

Cantor Fitzgerald

Eric Schmidt

Buy

Reiterates

n/a

2024-09-05

Reason

Cantor Fitzgerald

Eric Schmidt

Price Target

n/a

2024-09-05

Reiterates

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Immatics NV (IMTX.O) is -4.29, compared to its 5-year average forward P/E of -1.06. For a more detailed relative valuation and DCF analysis to assess Immatics NV 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.06

Current PE

-4.29

Overvalued PE

1.15

Undervalued PE

-3.26

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.46

Current EV/EBITDA

-1.09

Overvalued EV/EBITDA

1.40

Undervalued EV/EBITDA

-8.31

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

10.97

Current PS

11.67

Overvalued PS

15.36

Undervalued PS

6.58